Drug Profile
Research programme: hyperlipidaemia therapeutics - Acasti Pharma
Alternative Names: Omega-3 phospholipidLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Acasti Pharma
- Class Phospholipids
- Mechanism of Action Lipid modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hyperlipidaemia
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Hyperlipidaemia in Canada (PO)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Hyperlipidaemia in USA (PO)
- 23 Sep 2010 Preclinical pharmacodynamics data in Hyperlipidaemia released by Acasti Pharma